Indication
In combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma
Medicine details
- Medicine name:
- daratumumab (Darzalex)
- SMC ID:
- SMC2891
- Pharmaceutical company
- Johnson & Johnson
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC